Top-3 Best Biopharma Stocks to Watch

Brandie E Blackler
9 Min read

The pharma industry is a massive one and encompasses several segments. Among those is biopharma, which is likely set to become increasingly popular in the health sector.

One of the fastest-growing segments within the pharma industry, biopharma is likely well-positioned to keep on the rise.

We are living in what’s been referred to, multiple times, as a “golden age” in pharmaceutics. Thanks to technological advances, the pharma industry has made several groundbreaking discoveries, leading to innovative drugs and treatments. In this context, it’s no wonder that biopharma stocks have been drawing plenty of interest from investors.

In this article, we will take a closer look at the biopharma industry, its definition, as well as how to invest in biopharma stocks, while also outlining their pros and cons.

If this sounds interesting, let’s get started.

Best Biopharma Stocks: Introduction

Before we take a look at biopharma stocks, we first should look at the definition of biopharma itself. A biopharmaceutical is a product developed using living organisms - cells. These cells are genetically manipulated to produce specific substances, such as proteins, sugars, and other complex molecules.

It’s worth noting that biopharmaceuticals are different from other biological treatments, such as blood and organ transplants. While the latter are directly extracted from living beings, biopharmaceuticals are substances produced by other living organisms.

Vaccines are an example: while regular vaccines are usually made of attenuated pathologic agents, such as weakened viruses, biopharmaceutic vaccines are developed by injecting specific genes into other cells, which will then produce certain proteins that will stimulate the organism’s immune response. mRNA vaccines, like the COVID-19 vaccines developed by AstraZeneca and Moderna, are two examples of biopharmaceuticals.

Compared to regular pharmaceuticals, biopharma products offer some advantages, which can include reduced side effects, improved precision and efficiency, biodegradability, and personalized treatments that can target specific pathogens.

What are Biopharma Stocks?

Investors interested in the biopharma segment can invest in biopharma stocks. The biopharma industry has grown significantly in size. Some of the biggest names from the pharma industry have made major investments in biopharma. But the segment also has plenty of medium-sized companies and smaller startups.

The biopharma industry has raised over $230 billion in investment every year since 2021. Research and development (R&D) in the pharma industry is expensive, and that’s especially true when it comes to biopharma. On the other hand, the returns are potentially high and could justify the principal investment.

Treatments for cancer and other still incurable diseases, such as type-1 diabetes, are the leading areas in biopharma. With the potential for breakthrough discoveries in the next few years, biopharma stocks could be worth a look if you want to diversify your portfolio.

At Admirals, you can start with a demo account, which does not use real assets. This way, you can learn the ins and outs risk-free, without having to worry about losses, while you come up with your strategy. After that, you can sign up for a live account to use your assets. At Admirals, you can start investing with as little as $1, with access to multiple markets.

Risk Free Demo Account

Register for a free online demo account and practise your trading strategy

Best Biopharma Stocks: Advantages and Disadvantages

Before you decide to invest in biopharma stocks, it’s important to learn about their pros and cons. All investments have advantages and disadvantages after all, and it’s no different for biopharma stocks.


  • The pharmaceutical industry has often been a favourite among investors, as it’s considered one of the top defensive stocks. In other words, these stocks tend to do well even in bear markets. That’s also the case for biopharma stocks since all major pharma companies are also part of the biopharma segment. 
  • As previously mentioned, there have been multiple groundbreaking discoveries in medical research. Major technological advances, such as AI, are set to continue, which could lead to gains for biopharma stocks. 
  • Companies continue to ramp up investment in biopharma R&D, which has led to an increasing number of products either hitting the market or already in the late stages of development. This could also generate bigger returns to biopharma stocks.


  • R&D is very expensive. While most pharma companies can make up for their investments, there is always the risk of R&D investments not paying off - which does happen from time to time. Getting approval from regulatory agencies, such as the US Food and Drug Administration (FDA), is arguably the biggest obstacle. 
  • Some biopharmaceuticals have relatively limited usage and are aimed at extremely specific groups. As a result, these products tend to be extremely expensive, and that can potentially damage returns. 
  • Because of R&D costs, the biopharma segment is made up mostly of big pharma companies, and a few mid-sized ones. Biopharma startups have a hard time establishing themselves, which means that finding good growth stocks can be quite difficult.

Top 3 Best Biopharma Stocks to Watch

We will now take a look at some of the best biopharma stocks available for you to invest in, as well as their advantages and disadvantages.

Pfizer (PFE)

The American pharmaceutical company has invested heavily in the biopharma segment, either acquiring other companies or establishing partnerships.

Advantage of Pfizer stocks:

  • Pfizer can be considered a “buy and forget about it” stock. The American pharmaceutics giant has a consistent and stable dividend yield and tends to do well even when the market is trending down.

Disadvantage of Pfizer stocks:

  • After experiencing impressive growth during the pandemic, driven largely by its COVID-19 vaccine, Pfizer stocks lost value over the past year. The company’s loss in revenue happened largely because of the drop in demand for COVID-related products.

<h3>Johnson & Johnson (JNJ)

The world’s biggest pharmaceutical company by revenue, Johnson & Johnson has, unsurprisingly, invested heavily in biopharmaceuticals. Most recently, the American multinational acquired Ambrx, a biopharma drug maker that specializes in cancer treatment.

Advantage of Johnson & Johnson stocks:

  • Johnson & Johnson has been around for well over a century, and the company remains as stable as ever. The American multinational provides investors with stable and consistent dividend yields.

Disadvantage of Johnson & Johnson stocks:

  • While Johnson & Johnson does provide relatively stable returns, it also means that there is little room for growth. It’s been almost 15 years since Johnson & Johnson last registered growth rates in the double digits.

AbbVie Inc. (ABBV)

AbbVie is best known for its flagship product, Humira - a biopharmaceutical for rheumatoid arthritis treatment. Humira was the world’s most prescribed and best-selling drug for nearly a decade. The majority of AbbVie’s revenue comes from biopharmaceuticals as well.

Advantage of AbbVie stocks:

  • Abbvie continues to strengthen its position in the biopharma segment with smart investments. The company recently acquired Cerevel Therapeutics and Immunogen, two important biopharma companies focused, respectively, on neurological and oncological treatment.

Disadvantage of AbbVie stocks:

  • Abbvie’s patent for its flagship drug, Humira, expired in 2023. The company is set to experience the effects this year, however, as competition from generic biosimilars should take a toll on sales.

How to Buy Biopharma Stocks

You can buy biopharma stocks through a reliable and regulated broker, like Admirals. This is the easiest and safest way to invest in biopharma stocks.

Admirals supports MetaTrader 5, the top platform for multi-asset investing and trading. With MetaTrader 5, you will have plenty of features available:

  • Easy, user-friendly platform. 
  • Superior, personalized charting. 
  • Free access to market data and news. 
  • Educational tools. 
  • Automated trading with AI bots. 

The world's premier multi-asset platform

Best Biopharma Stocks to Watch: Conclusion

Biopharma stocks are a possible alternative if you want exposure to the pharma industry. As one of the fastest-growing segments within the pharma industry, biopharma can potentially provide good returns (with always the possibility of risk, as well). The biggest companies in the pharma industry are also present in the biopharma segment, so you will be able to find plenty of interesting stocks to invest in.

Keep in mind that, just like any other investment, biopharma stocks can have drawbacks as well. The biopharma segment is extremely expensive, which makes it difficult for startups to thrive, so finding stocks with above-average growth can be tricky. Costs and returns are both high, and it’s important to understand the risks and benefits of investing in bigger or smaller companies.


The given data provides additional information regarding all analysis, estimates, prognosis, forecasts, market reviews, weekly outlooks or other similar assessments or information (hereinafter “Analysis”) published on the websites of Admirals' investment firms operating under the Admirals trademark (hereinafter “Admirals”). Before making any investment decisions, please pay close attention to the following:

  1. This is marketing communication. The content is published for informative purposes only and is in no way to be construed as investment advice or recommendation. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and that it is not subject to any prohibition on dealing ahead of the dissemination of investment research. 
  2. Any investment decision is made by each client alone whereas Admirals shall not be responsible for any loss or damage arising from any such decision, whether or not based on the content. 
  3. With view to protecting the interests of our clients and the objectivity of the Analysis, Admirals has established relevant internal procedures for the prevention and management of conflicts of interest. 
  4. The Analysis is prepared by an independent analyst (hereinafter “Author”) based on Brandie E Blackler, Financial Analyst, personal estimations. 
  5. Whilst every reasonable effort is taken to ensure that all sources of the content are reliable and that all information is presented, as much as possible, in an understandable, timely, precise and complete manner, Admirals does not guarantee the accuracy or completeness of any information contained within the Analysis. 
  6. Any kind of past or modeled performance of financial instruments indicated within the content should not be construed as an express or implied promise, guarantee or implication by Admirals for any future performance. The value of the financial instrument may both increase and decrease and the preservation of the asset value is not guaranteed. 
  7. Leveraged products (including contracts for difference) are speculative in nature and may result in losses or profit. Before you start trading, please ensure that you fully understand the risks involved.
Meet the GRANOLAS Stocks
The GRANOLAS are a group of 11 European stocks which, between them, have accounted for roughly 50% of the gains posted by the STOXX 600 index over the last year. Keep reading to learn more about the GRANOLAS stocks, which are drawing comparisons with their transatlantic rivals, the “Magnificent Seve...
Investing in Uranium Stocks
Uranium is widely used as fuel for nuclear power plants and, therefore, is a critical component of producing nuclear energy. Nuclear energy has been largely maligned for more than a decade, but there have been recent signs that it may be making a comeback which could, in turn, increase demand for ur...
Should I Invest in Tesla?
Electric Vehicle (EV) ownership is on the rise and, due to high oil prices and the need to reduce our emissions, it is a fairly safe assumption that demand for EVs will continue to rise in the future. Although competition has increased recently in the EV sector, there is still one undisputed king: T...
View All